Greenwich LifeSciences (GLSI) investor relations material

Executive summary

• Focused on Phase III clinical trial Flamingo-01 for GLSI-100, an immunotherapy to prevent breast cancer recurrence; expanding trial to Europe with up to 150 global sites.

• No revenue generated to date; net losses driven by R&D and administrative costs.

• Net loss for six months ended June 30, 2026 was $9.6 million, up from $6.5 million in the prior year period.

Financial highlights

• Cash balance as of June 30, 2026 was $8.88 million, up from $6.18 million at December 31, 2025.

• Net loss for Q2 2026 was $3.95 million, compared to $3.75 million in Q2 2025.

• Operating expenses for six months ended June 30, 2026 were $9.75 million, up from $6.54 million year-over-year.

• Research and development expenses rose 54% year-over-year for the six-month period, primarily due to increased clinical expenses and option grants.

• General and administrative expenses increased 15% year-over-year for the six-month period, mainly from option grants.

Outlook and guidance

• Expects continued significant expenses and operating losses as clinical development and infrastructure build-out continue.

• Additional capital will be required to meet long-term operating requirements; plans to raise funds through equity or debt offerings.